The next focus for tofersen therapy is to evaluate the effects in presymptomatic carriers of SOD1 mutation, and the ATLAS study (NCT04856982) has been designed to investigate whether tofersen can delay the emergence of clinically manifested ALS.14 The gene discussed is SOD1; the disease is amyotrophic lateral sclerosis.